Key facts
- Toralgen’s last known valuation is $28.3M (Oct 2020).
- It has raised $13.0M; the latest was Later Stage VC ($4.7M) in Feb 2025.
- Notable investors include Elevate Ventures, Solyco Capital, Talon Group, VisionTech Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Toralgen
- ·The full record, as it builds
Funding rounds
No funding rounds for Toralgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toralgen
Operator of a preclinical stage biopharmaceutical company intended to focus on the development and commercialization of human therapeutics. The company offers a poly-bile nano-particle platform that eliminates the challenges of oral delivery to fabricate nano-pill and improve outcomes through optimized and targeted drug delivery, enabling healthcare providers to improve the lives of their patients.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2017
- Employees
- 9
- Website
- toralgen.com/
- Ownership
- Privately Held (backing)
Toralgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toralgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toralgen in its N-PORT filings yet. We sweep new filings monthly.